Mylan (MYL) Given a $31.00 Price Target at Cowen

Cowen set a $31.00 target price on Mylan (NASDAQ:MYL) in a research note released on Tuesday morning. The brokerage currently has a hold rating on the stock.

Several other brokerages have also issued reports on MYL. Cantor Fitzgerald reissued a hold rating and issued a $41.00 price target on shares of Mylan in a report on Wednesday, August 8th. Wells Fargo & Co set a $41.00 target price on shares of Mylan and gave the stock a hold rating in a report on Wednesday, August 8th. Leerink Swann lowered their target price on shares of Mylan from $53.00 to $47.00 and set an outperform rating on the stock in a report on Thursday, August 9th. Raymond James lowered shares of Mylan from a strong-buy rating to an outperform rating in a report on Thursday, August 9th. Finally, ValuEngine raised shares of Mylan from a sell rating to a hold rating in a report on Tuesday, August 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $46.87.

Mylan stock traded down $0.20 on Tuesday, hitting $36.95. The company’s stock had a trading volume of 4,300,237 shares, compared to its average volume of 6,462,479. The firm has a market capitalization of $18.84 billion, a PE ratio of 8.10, a price-to-earnings-growth ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77. Mylan has a one year low of $30.33 and a one year high of $47.82.

Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 5th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.19 by $0.06. The firm had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.91 billion. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The business’s revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.10 EPS. Analysts predict that Mylan will post 4.68 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Pzena Investment Management LLC grew its holdings in Mylan by 2.6% during the 3rd quarter. Pzena Investment Management LLC now owns 21,657,877 shares of the company’s stock worth $792,678,000 after acquiring an additional 542,725 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Mylan by 8.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 10,226,277 shares of the company’s stock worth $374,280,000 after acquiring an additional 818,059 shares during the last quarter. FMR LLC grew its holdings in Mylan by 1.9% during the 2nd quarter. FMR LLC now owns 9,171,840 shares of the company’s stock worth $331,470,000 after acquiring an additional 168,347 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Mylan by 2.7% during the 2nd quarter. Janus Henderson Group PLC now owns 5,389,463 shares of the company’s stock worth $194,776,000 after acquiring an additional 144,075 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Mylan by 14.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,132,430 shares of the company’s stock worth $185,499,000 after acquiring an additional 644,643 shares during the last quarter. 82.99% of the stock is currently owned by institutional investors and hedge funds.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

See Also: Google Finance Portfolio Workaround

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit